JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the receipt of a positive opinion from the CHMP, the scientific committee of the European Medicines Agency (“EMEA”), for its human granulocyte colony stimulating factor (“G-CSF”) product. Teva’s product is the first biosimilar G-CSF to receive a positive opinion in the European Union.
